Heat Biologics, Inc.

Leading the Immuno-Oncology Revolution

Heat’s ImPACT Immunotherapy transforms living allogeneic human cancer cells into miniature osmotic pumps that continually secrete cancer antigens to activate a patient's own immune system to destroy the cancer cells.

Learn more about our science

About Us

Heat Biologics is a clinical-stage company focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic "off-the-shelf" cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

Learn more about Heat Biologics

View our corporate presentation

Recent News

Heat Biologics Prices 5,813,950 Shares for Common Stock Offering

Read More

Heat Biologics Announces Proposed Public Offering of Common Stock

Read More

Events

November 8, 2017 - November 12, 2017

Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

October 17, 2017 - October 18, 2017

BIO Investor Forum

ImPACT Therapy

A First-In-Class Fully Human Cytotoxic T Cell Specific Adjuvant

Heat Biologics’ proprietary ImPACT technology transforms allogenic living cells into miniature osmotic pumps that continually secrete heat shock protein gp96, the most potent mammalian adjuvant ever described, along with its chaperoned antigens.

View our product pipeline